Product Description
Burapitant (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK1 receptor. Burapitant inhibited the binding of radioactive substance P to tachykinin NK1 receptors in human lymphoblastic IM9 cells, human astrocytoma U373MG cells, and human brain cortex. (Sourced from: https://drugs.ncats.io/drug/E35SK332MS)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Overactive Bladder|Urinary Incontinence, Urge|Enuresis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2007-004126-24 | P2 |
Completed |
Overactive Bladder|Urinary Incontinence, Urge |
2009-02-07 |
|
BILADY | P2 |
Completed |
Urinary Incontinence, Urge|Overactive Bladder |
2009-02-01 |
|
MILADY | P2 |
Completed |
Enuresis|Urinary Incontinence, Urge|Overactive Bladder |
2006-05-01 |